Columbia professor says PACE damaging Lancet’s reputation

Share on facebook
Share on twitter
Share on email

Yesterday, Columbia University professor of statistics Andrew Gelman published a warning that The Lancet was risking its reputation by refusing to rectify errors in the main paper on the PACE trial that appeared in the journal in 2011.
In his article on a popular statistics blog, Professor Gelman described the PACE authors’ refusal to share data from the study as “unforgivable”. In a reference to the much-criticised “normal range” analyses that appeared in the Lancet paper, he said, “No paper with an analysis in which you can get worse and be counted as improved should ever be published.”
Professor Gelman said that despite this “absurd” analysis, PACE has been presented as “definitive” in  the scientific literature and by public health agencies. He said that he suspects that the trial has stood so long because “The Lancet’s brand name gave this paper a pass.”
He noted that although Lancet editor Richard Horton said that the paper had undergone “endless rounds of peer review”, it is flagged online as having been “fast-tracked”, a process that takes four weeks according to current Lancet policy.
Professor Gelman said that, regardless of whether the paper had been reviewed repeatedly or very little, typically “reviewers have neither access to the raw data nor the time for careful reanalysis” and that “mistakes are inevitable.” But, he said, “What I can’t excuse is the journal editor’s dogged defense of a flawed paper.”
He went on to argue that if a poor paper was allowed to hide behind a journal’s reputation then it was right that the journal’s reputation should be degraded. He said, “The Lancet editor is using his journal’s reputation to defend the controversial study. But, as the study becomes more and more disparaged, the sharing of reputation goes the other way.”
Professor Gelman described imagining a scientist in future saying, “The Lancet, eh? Isn’t that the journal that published the discredited Iraq survey, the Andrew Wakefield paper, and that weird PACE study?”
He concluded his article by saying, “Long run, reputation should catch up to reality. But before the long run comes, there are a few people out there with chronic fatigue syndrome who don’t feel like waiting.”
Professor Gelman recently published two other articles critical of PACE (here and here). He is one of a growing band of academics who have become interested in the shortcomings of the PACE trial since a series of critical blog posts by Dr. David Tuller, Professor James Coyne and others in recent months.
The PACE trial was a £5 million randomised trial whose authors claim that it showed that cognitive therapy and graded exercise are beneficial for chronic fatigue syndrome patients.

Share on facebook
Facebook
Share on twitter
Twitter
Share on whatsapp
WhatsApp
Share on email
Email

2 thoughts on “Columbia professor says PACE damaging Lancet’s reputation”

Leave a Comment

Your email address will not be published. Required fields are marked *

Latest News

New Black British support group seeks members with ME and Long Covid

Darren Randon, co-founder of Well Versed Ink, is seeking new members for an online group for UK-based Black and Black-mixed adults living with diagnosed or suspected ME or Long-Covid. Formal diagnosis is not required. The group meets every other Sunday from 1-2pm. It provides a safe space to share experiences and create community, with the

Read More »
twelve circles indicate a day that pacing will be discussed. The circles are on top of a blue background.

12 Days of Pacing Begins Today!

12 Days of Pacing Begins Today! Welcome to #MEAction’s 12 Days of Pacing! For the next 12 days will work through what #StopRestPace really means and how to apply it practically in your life. We are excited to share some great tips from our amazing community along the way. We hope you will view this

Read More »
Logo for NPR's All Things Considered

NPR Features #MEAction in Series about Long COVID

NPR featured #MEAction in an article about long COVID called, “For patients with long COVID, chronic fatigue syndrome may offer a guiding star.”  MEAction’s Director of Scientific and Medical Outreach, Jaime Seltzer, speaks about how long COVID researchers and doctors must learn from the ME/CFS community. “People with chronic complex disease have been living with

Read More »

Help keep our work going

We rely on donations from people like you to keep fighting for equality for people with ME.

Donate

Get actions alerts and news direct to your inbox

You can choose what you want to be kept up to date on.

Subscribe
Scroll to Top